Rep. Scott Franklin buys Accenture, McDonald's shares in August
- Rep. Scott Franklin bought Accenture and McDonald's shares on August 26, 2026
- Transaction values range from $1,001 to $15,000 per trade
- Filings also include purchases in Novo Nordisk and Lord Abbett funds
- Franklin has executed 180 trades worth over $5.05 million in three years
*this image is generated using AI for illustrative purposes only.
Florida Representative Scott Franklin purchased shares in Accenture (NYSE: ACN) and McDonald's (NYSE: MCD) on August 26, 2026. The congressional disclosure filed on September 17, 2026, lists the transaction values between $1,001 and $15,000 for each position.
The filings also reveal purchases in Novo Nordisk (NYSE: NVO) and Lord Abbett Short Duration High fund (LSYIX) on the same date. These transactions are part of Franklin's broader trading activity, which includes 180 trades totaling over $5.05 million over the past three years.
Recent Trading Activity
Franklin's recent portfolio adjustments include multiple purchases executed simultaneously. The disclosed transactions reflect a diversified approach across technology, consumer staples, and healthcare sectors.
| Company | Ticker | Amount | Transaction Type | Date |
|---|---|---|---|---|
| Accenture | ACN | $1,001 - $15,000 | Purchase | 2026-08-26 |
| Accenture | ACN | $1,001 - $15,000 | Purchase | 2026-08-26 |
| Lord Abbett Short Duration High | LSYIX | $1,001 - $15,000 | Purchase | 2026-08-26 |
| McDonald's | MCD | $1,001 - $15,000 | Purchase | 2026-08-26 |
| Novo Nordisk | NVO | $1,001 - $15,000 | Purchase | 2026-08-26 |
Regulatory Context
Under the STOCK Act signed by President Barack Obama in April 2012, members of Congress must file Periodic Transaction Reports within 45 days of a transaction. The law prohibits using private information for personal gain and mandates monthly disclosures.
What the Numbers Show
Franklin executed five distinct purchase transactions on August 26, 2026, all falling within the $1,001 to $15,000 value bracket. The simultaneous acquisition of positions in both Accenture and McDonald's suggests a coordinated rebalancing rather than isolated trades, given the identical timing and value ranges disclosed.
How might Rep. Franklin's simultaneous purchases in tech and consumer staples signal his views on the upcoming Q3 earnings reports for Accenture and McDonald's?
Given the recent volatility in healthcare stocks, does Franklin's entry into Novo Nordisk suggest an expectation of sustained demand for GLP-1 agonists despite potential regulatory scrutiny?
Could this diversified rebalancing indicate a shift in legislative priorities regarding technology regulation or agricultural subsidies that might impact these specific sectors?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
